144 related articles for article (PubMed ID: 32323895)
81. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
82. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
Busch CJ; Kröger MS; Jensen J; Kriegs M; Gatzemeier F; Petersen C; Münscher A; Rothkamm K; Rieckmann T
Radiother Oncol; 2017 Feb; 122(2):260-266. PubMed ID: 27939202
[TBL] [Abstract][Full Text] [Related]
83. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
Tai TS; Lin PM; Wu CF; Hung SK; Huang CI; Wang CC; Su YC
Anticancer Res; 2019 Feb; 39(2):713-720. PubMed ID: 30711949
[TBL] [Abstract][Full Text] [Related]
84. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
[TBL] [Abstract][Full Text] [Related]
85. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
Moore K; Zhang ZY; Agarwal S; Burris H; Patel MR; Kansra V
Cancer Chemother Pharmacol; 2018 Mar; 81(3):497-503. PubMed ID: 29322231
[TBL] [Abstract][Full Text] [Related]
86. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
87. Comparative Therapeutic Exploitability of Acute Adaptation Mechanisms to Photon and Proton Irradiation in 3D Head and Neck Squamous Cell Carcinoma Cell Cultures.
Meerz A; Deville SS; Müller J; Cordes N
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801853
[TBL] [Abstract][Full Text] [Related]
88. Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma.
Mueller S; Bhargava S; Molinaro AM; Yang X; Kolkowitz I; Olow A; Wehmeijer N; Orbach S; Chen J; Matthay KK; Haas-Kogan DA
Anticancer Res; 2013 Mar; 33(3):755-62. PubMed ID: 23482742
[TBL] [Abstract][Full Text] [Related]
89. Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress.
Bezrookove V; Patino JM; Nosrati M; Desprez PY; McAllister S; Soroceanu L; Baron A; Osorio R; Kashani-Sabet M; Dar AA
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503215
[TBL] [Abstract][Full Text] [Related]
90. Personalized Assessment of Normal Tissue Radiosensitivity via Transcriptome Response to Photon, Proton and Carbon Irradiation in Patient-Derived Human Intestinal Organoids.
Nowrouzi A; Sertorio MG; Akbarpour M; Knoll M; Krunic D; Kuhar M; Schwager C; Brons S; Debus J; Wells SI; Wells JM; Abdollahi A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085439
[TBL] [Abstract][Full Text] [Related]
91. Switching PARP inhibitors as an effective approach for niraparib-induced erythema multiforme.
Pesqué D; Tormo-Mainar S; Bach R; Recuero-Borau J; Pujol RM
Int J Dermatol; 2022 Oct; 61(10):e407-e408. PubMed ID: 35080014
[No Abstract] [Full Text] [Related]
92. The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma.
Wang L; Fossati P; Paganetti H; Ma L; Gillison M; Myers JN; Hug E; Frank SJ
Int J Part Ther; 2021; 8(1):3-13. PubMed ID: 34285931
[TBL] [Abstract][Full Text] [Related]
93. Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation.
Césaire M; Ghosh U; Austry JB; Muller E; Cammarata FP; Guillamin M; Caruso M; Castéra L; Petringa G; Cirrone GAP; Chevalier F
J Bone Oncol; 2019 Aug; 17():100246. PubMed ID: 31312595
[TBL] [Abstract][Full Text] [Related]
94. Overcoming radioresistance in WiDr cells with heavy ion irradiation and radiosensitization by 2-deoxyglucose with photon irradiation.
Hasse FC; Koerber SA; Prigge ES; Liermann J; von Knebel Doeberitz M; Debus J; Sterzing F
Clin Transl Radiat Oncol; 2019 Nov; 19():52-58. PubMed ID: 31517070
[TBL] [Abstract][Full Text] [Related]
95. Short-term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy.
Zhi W; Li S; Wan Y; Wu F; Hong L
Cancer Cell Int; 2022 Jan; 22(1):18. PubMed ID: 35016681
[TBL] [Abstract][Full Text] [Related]
96. Comparative Proton and Photon Irradiation Combined with Pharmacological Inhibitors in 3D Pancreatic Cancer Cultures.
Görte J; Beyreuther E; Danen EHJ; Cordes N
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142778
[TBL] [Abstract][Full Text] [Related]
97. Photon- and Proton-Mediated Biological Effects: What Has Been Learned?
Jumaniyazova E; Smyk D; Vishnyakova P; Fatkhudinov T; Gordon K
Life (Basel); 2022 Dec; 13(1):. PubMed ID: 36675979
[TBL] [Abstract][Full Text] [Related]
98. Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges.
Nuyts S; Bollen H; Ng SP; Corry J; Eisbruch A; Mendenhall WM; Smee R; Strojan P; Ng WT; Ferlito A
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681568
[TBL] [Abstract][Full Text] [Related]
99. How to start niraparib in real-world Asian ovarian cancer patients?
Hong SH
J Gynecol Oncol; 2021 Mar; 32(2):e36. PubMed ID: 33559417
[No Abstract] [Full Text] [Related]
100. Niraparib for ovarian cancer.
Aust Prescr; 2021 Dec; 44(6):208-209. PubMed ID: 35002037
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
